1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al.International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-28. DOI: 10.1182/blood.2022015850.
2. Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf ofthe ELN. Blood. 2022;140(12):1345-77. DOI: 10.1182/ blood.2022016867.
3. The WHO Classification of Tumours Editorial Board (eds.). WHO classification of tumours. Haematolymphoid tumours. V. 1. 5th ed. Lyon: IARC, 2024. 958 p.
4. Воропаева Е.Н., Бурундукова М.В., Лызлова А.А., Чухонцева И.А., Максимов В.Н., Поспелова Т.И. Мутации в «горячих» точках генов FLT3, NPM1, IDH1, IDH2 и DNMT3A при остром миелоидном лейкозе. Сибирский онкологический журнал. 2025;24(1): 125-141. DOI: 10.21294/1814-48612025-24-1-125-141.
Voropaeva EN, Burundukova MV, Lyzlova AA, Chukhontseva IA, Maksimov VN, Pospelova TI. Mutations in the “hot spots” of the FLT3, NPM1, IDH1, IDH2 and DNMT3A genes in acute myeloid leukemia. Siberian Journal of Oncology. 2025; 24(1):125-141 (In Russ.). DOI: 10.21294/1814-4861-2025-24-1-125-141.
5. Li JF, Cheng WY, Lin XJ, Wen LJ, Wang K, Zhu YM et al. Aging and comprehensive molecular profiling in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2024;121(10):e2319366121. DOI: 10.1073/pnas.2319366121.
6. Popov A, Tsaur G, Permikin Z, Henze G, Verzhbitskaya T, Plekhanova O et al. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: results of MLL-Baby protocol. Pediatr Blood Cancer. 2023;70(4):e30204. DOI: 10.1002/pbc.30204.
7. Виноградов А.В., Резайкин А.В., Сазонов С.В., Сергеев А.Г., Капитонова М.Ю. Молекулярно-генетический анализ мутаций в генах ASXL1, FLT3, KIT, NPM1, NRAS, TP53 и WT1 у больных острыми миелоидными лейкозами зрелого возраста. Медицинский вестник Северного Кавказа. 2020;15(1):32-36. DOI: 10.14300/mnnc.2020.15006.
Vinogradov AV, Rezaykin AV, Sazonov SV, Sergeev AG, Kapitonova MYu. Molecular genetic analisys of ASXL1, FLT3, KIT, NPM1, NRAS, TP53 and WT1 mutations in acute myeloid leukemia patients 45-60 years old. Medical News of North Caucasus. 2020;15(1):32-36 (In Russ.). DOI: 10.14300/mnnc. 2020.15006.
8. Виноградов А.В., Резайкин А.В., Сергеев А.Г. Детекция внутренних тандемных дупликаций и точковых мутаций гена FLT3 при острых миелоидных лейкозах методом прямого автоматического секвенирования. Вестник Уральской медицинской академической науки. 2013;43(1):64-66. Доступно по адресу: https://www.elibrary.ru/item.asp?id=18964670 (получено 02.07.2025).
Vinogradov AV, Rezaikin AV, Sergeev AG. Detection of FLT3 gene internal tandem duplications and tyrosine kinase domain mutations in acute myeloid leukemia using automated sequencing technique. Journal of Ural Medical Academic Science. 2013;43(1):64-66 (In Russ.). Available from: https://www.elibrary.ru/item.asp?id=18964670 (accessed 02.07.2025).
9. Цаур Г.А., Ольшанская Ю.В., Обухова Т.Н., Судариков А.Б., Лазарева О.В., Гиндина Т.Л. Цитогенетическая и молекулярно-генетическая диагностика онкогематологических заболеваний: позиция организации молекулярных генетиков в онкологии и онкогематологии. Гематология и трансфузиология. 2023;68(1):129-143. DOI: 10.35754/0234-5730 2023-68-1-129-43.
Tsaur GA, Olshanskaya YuV, Obukhova TN, Sudarikov AB, Lazareva OV, Gindina TL. Cytogenetic and molecular genetic diagnostics in oncohematological disorders: a position paper of the organization of molecular geneticists in oncology and oncohematology.Russian journal of hematology and transfusiology. 2023;68(1):129-143 (In Russ.). DOI: 10.35754/02345730-2023-68-1-129-143.
10. Виноградов А.В., Резайкин А.В., Изотов Д.В., Сергеев А.Г. Применение технологии прямого автоматического секвенирования для детекции мутаций генов ASXL1, DNMT3A, FLT3, KIT, NRAS, TP53 и WT1 при острых миелоидных лейкозах c неуточненным кариотипом. Вестник Уральской медицинской академической науки. 2016;59(4):38-51. DOI: 10.22138/25000918-2016-14-4-38-51.
Vinogradov AV, Rezaykin AV, Izotov DV. Sergeev AG. ASXL1, DNMT3A, FLT3, KIT, NRAS, TP53 and WT1 genes mutations detection in acute myeloid leukemia with unspecified karyotype using direct sequencing technique. Journal of Ural Medical Academic Science. 2016;59(4):38-51 (In Russ.). DOI: 10.22138/2500-0918-2016-14-4-38-51.
11. Lilljebjorn H, Orsmark-Pietras C, Mitelman F, Hagstrom-Andersson A, Fioretos T. Transcriptomics paving the way for improved diagnostics and precision medicine of acute leukemia. Semin Cancer Biol. 2022;84:40-9. DOI: 10.1016/j. semcancer.2021.09.013.
12. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526-31. DOI: 10.1038/s41586-018-0623-z.
13. Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Groger D, Sutton R et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37(5):988-1005. DOI: 10.1038/s41375-023-01877-1.
14. Silbert SK, Rankin AW, Hoang CN, Semchenkova A, Myers RM, Zerkalenkova E et al. Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia. Blood. 2025;146(4):437-55. DOI: 10.1182/ blood.2024026655.
15. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823-33. DOI: 10.1038/nrc2253.
16. Guarnera L, D’Addona M, Bravo-Perez C, Visconte V. KMT2A rearrangements in leukemias: molecular aspects and therapeutic perspectives.Int J Mol Sci. 2024;25(16):9023. DOI: 10.3390/ ijms25169023.
17. Aubrey BJ, Cutler JA, Bourgeois W, Donovan KA, Gu S, Hatton C et al. IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nat Cancer. 2022;3(5):595-613. DOI: 10.1038/s43018-022-00366-1.
18. Hyrenius-Wittsten A, Pilheden M, Sturesson H, Hansson J, Walsh MP, Song G et al. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. Nat Commun. 2018;9(1):1770. DOI: 10.1038/s41467-018-04180-1.
19. Hernandez-Sanchez A, Gonzalez T, Sobas M, Strang E, Castellani G, Abaigar M et al. Rearrangements involving 11q23.3/ KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study. Leukemia. 2024;38(9):1929-DOI: 10.1038/s41375-024-02333-4.
20. Mer AS, Heath EM, Madani Tonekaboni SA, Dogan-Artun N, Nair SK, Murison A et al. Biological and therapeutic implications of a unique subtype of NPM1 mutated AML. Nat Commun. 2021;12(1):1054. DOI: 10.1038/s41467-021-21233-0.
21. Cheng WY, Li JF, Zhu YM, Lin XJ, Wen LJ, Zhang F et al. Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022;119(49):e2211429119. DOI: 10.1073/pnas.2211429119.
22. Bisegna ML, Peragine N, Elia L, Matarazzo M, Milani ML, Intoppa S et al. NG2 molecule expression in acute lymphoblastic leukemia B cells: a flow-cytometric marker for the rapid identification of KMT2A gene rearrangements. Mediterr J Hematol Infect Dis. 2024;16(1):e2024018. DOI: 10.4084/ MJHID.2024.018.
23. Zerkalenkova E, Mikhaylova E, Lebedeva S, Illarionova O, Baidun L, Kashpor S et al. Quantification of NG2-positivity for the precise prediction of KMT2A gene rearrangements in childhood acute leukemia. Genes Chromosomes Cancer. 2021;60(2):88-99. DOI: 10.1002/gcc.22915.